Sökning: WFRF:(Maisel A)
> (2010-2014) >
Effect of Spironola...
Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH Study)
-
- Maisel, Alan (författare)
- University of Calif San Diego, CA 92103 USA
-
- Xue, Yang (författare)
- University of Calif San Diego, CA 92103 USA
-
- van Veldhuisen, Dirk J. (författare)
- University of Groningen, Netherlands
-
visa fler...
-
- Voors, Adriaan A. (författare)
- University of Groningen, Netherlands
-
- Jaarsma, Tiny (författare)
- Linköpings universitet,Hälsa, Aktivitet, Vård (HAV),Hälsouniversitetet
-
- Pang, Peter S. (författare)
- Northwestern University, IL 60611 USA
-
- Butler, Javed (författare)
- Emory University, GA 30322 USA
-
- Pitt, Bertram (författare)
- University of Michigan, MI 48109 USA
-
- Clopton, Paul (författare)
- University of Calif San Diego, CA 92103 USA
-
- de Boer, Rudolf A. (författare)
- University of Groningen, Netherlands
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2014
- 2014
- Engelska.
-
Ingår i: American Journal of Cardiology. - : Elsevier. - 0002-9149 .- 1879-1913. ; 114:5, s. 737-742
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy. were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.
Ämnesord
- SAMHÄLLSVETENSKAP -- Sociologi (hsv//swe)
- SOCIAL SCIENCES -- Sociology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Maisel, Alan
-
Xue, Yang
-
van Veldhuisen, ...
-
Voors, Adriaan A ...
-
Jaarsma, Tiny
-
Pang, Peter S.
-
visa fler...
-
Butler, Javed
-
Pitt, Bertram
-
Clopton, Paul
-
de Boer, Rudolf ...
-
visa färre...
- Om ämnet
-
- SAMHÄLLSVETENSKAP
-
SAMHÄLLSVETENSKA ...
-
och Sociologi
- Artiklar i publikationen
-
American Journal ...
- Av lärosätet
-
Linköpings universitet